9 Meters Biopharma Company Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America.
Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome.
The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease.
Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome.
The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS.
9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
Contact Details
Address: 4509 Creedmoor Road Raleigh, Delaware 27612 United States | |
| Phone | 919 275 1933 |
| Website | 9meters.com |
Stock Details
| Ticker Symbol | NMTRQ |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US6544052086 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter H. R. Green M.D. | Clinical and Scientific Advisor and Consultant |
| Joseph A. Murray M.D. | Clinical and Scientific Advisor and Consultant |
| Dr. Ciaran P. Kelly M.D. | Clinical and Scientific Advisor and Consultant |
| Dr. Elena Verdu M.D., Ph.D. | Clinical and Scientific Advisor and Consultant |
| Markku Mäki M.D., Ph.D. | Clinical and Scientific Advisor and Consultant |
| Dr. William J. Sandborn M.D., Ph.D. | Clinical and Scientific Advisor and Consultant |
| Dr. Roger Liddle M.D. | Clinical and Scientific Advisor and Consultant |
| Dr. Anthony J. Dimarino Jr. | Clinical and Scientific Advisor and Consultant |
| Dr. Brian Gordon Feagan FRCPC, M.D., M.P.H. | Clinical and Scientific Advisor and Consultant |
| Dr. Aida Habtezion M.D., M.Sc. | Clinical and Scientific Advisor and Consultant |